After Axsome Therapeutics (AXSM) reported topline data from the studies of AXS-05 in Alzheimer’s disease agitation, Truist analyst Joon Lee noted that while the ADVANCE-2 study missed ...

ACCORD-2 trial shows AXS-05 significantly delays Alzheimer’s agitation relapse; long-term safety established, NDA submission planned for 2025. Axsome Therapeutics has announced positive results ...

Fintel reports that on February 11, 2025, Deutsche Bank initiated coverage of Axsome Therapeutics (NasdaqGM:AXSM) with a Buy ...

The ACCORD-2 Phase 3 trial achieved the primary endpoint with AXS-05 statistically significantly delaying the time to relapse of agitation, assessed by the Cohen-Mansfield Agitation Inventory ...

Axsome Therapeutics (AXSM) is climbing nearly 4% after Swiss bank UBS increased its price target on the shares to $133 from ...

Shares in Axsome Therapeutics have rocketed on FDA approval of its depression therapy Auvelity (formerly AXS-05) – a year after its approval was held up by the regulator. The FDA has cleared ...

Axsome Therapeutics (AXSM) announced the completion of its Phase 3 clinical program evaluating AXS-05 a novel, oral, investigational NMDA receptor antagonist, sigma-1 agonist, and aminoketone CYP2 ...

Axsome Therapeutics has announced that it has successfully completed its late-stage clinical programme evaluating investigational AXS-05 (dextromethorphan-bupropion) in Alzheimer’s disease (AD) ...

After having spoken with six doctors who treat Alzheimer’s disease agitation, the firm says those doctors “unanimously” viewed AXS-05’s totality of evidence as supportive of approval with ...

Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results Axsome's AXS-05 met endpoints in Alzheimer's agitation studies, showing long-term safety and tolerability.

The ACCORD-2 Phase 3 trial achieved the primary endpoint with AXS-05 statistically significantly delaying the time to relapse of agitation, assessed by the Cohen-Mansfield Agitation Inventory (CMAI) ...

Digital access Digital + home delivery TSX 0.44 % ...